Cancer clinical trial database.
Every new trial and trial result from New in Oncology, our weekly research briefing, since the first issue on . Search by NCT number, drug, or cancer type.
All entries in liver and bile duct cancer
- New trial
Liver and bile duct cancer
Phase 2 daraxonrasib pan-RAS(ON) tri-complex inhibitor targets KRAS-mutant biliary tract cancer.
This multi-institutional Phase 2, open-label, single-arm study evaluates daraxonrasib monotherapy in patients with unresectable or advanced/metastatic biliary tract cancers (including cholangiocarcinoma, gallbladder…
NCT07793253 Exploratory - Trial result
Liver and bile duct cancer
STRIDE (durvalumab + tremelimumab) + VEGFR/FGFR TKI lenvatinib + TACE extends PFS in embolisation-eligible HCC
STRIDE is dual-checkpoint immunotherapy (anti–PD-L1 durvalumab + single priming dose anti–CTLA-4 tremelimumab); lenvatinib is an oral multikinase inhibitor (VEGFR/FGFR/PDGFR/RET/KIT). In the global Phase 3 EMERALD-3…
NCT05301842 - New trial Spotlight
Liver and bile duct cancer
Phase 2a pemigatinib FGFR1/2/3 inhibitor alternated with durvalumab PD‑L1 blockade
This Ohio State University Comprehensive Cancer Center Phase 2a study tests a “cyclical/alternating” first-line strategy for unresectable, locally advanced, or metastatic biliary tract cancers (commonly intrahepatic…
NCT07780838 Exploratory - New trial
Liver and bile duct cancer
Phase 2 durvalumab PD-L1 inhibitor plus histotripsy non-thermal focused ultrasound ablation in iCCA
This single-group Phase 2 pilot study (CODAH) at the University of Wisconsin–Madison evaluates whether adding histotripsy to ongoing maintenance durvalumab increases anti-tumor immune activation and remains safe in…
NCT07766187 Exploratory - New trial Spotlight
Liver and bile duct cancer
Phase 2 zolbetuximab CLDN18.2-directed monoclonal antibody + CAPOX/mFOLFOX6 in BTC
Single-arm Phase 2 at the University of Alabama at Birmingham evaluates zolbetuximab, a CLDN18.2-targeted monoclonal antibody that can drive tumor cell killing via immune effector mechanisms (including ADCC and…
NCT07723534 Exploratory - Trial result
Liver and bile duct cancer
Rucaparib (PARP inhibitor) + nivolumab (PD-1) maintenance misses primary PFS bar in advanced BTC, with signal in DDR/IDH1 subsets
Rucaparib is an oral PARP inhibitor paired here with nivolumab, a PD-1 antibody, as switch-maintenance after 4-6 months of first-line platinum chemotherapy in advanced biliary tract cancer (BilT-02; Phase 2,…
NCT03639935 - Trial result
Liver and bile duct cancer
Atezolizumab (PD-L1) + bevacizumab (VEGF) in HCC: “on-target” TRAEs (renal/vascular/skin) track with longer OS
Atezolizumab is an anti–PD-L1 antibody and bevacizumab is an anti-VEGF antibody; this post hoc exploratory analysis pooled patients from IMbrave150 (NCT03434379) and GO30140 (NCT02715531) to test whether adverse…
NCT03434379 - Trial result
Liver and bile duct cancer
Durvalumab (PD-L1) + GemCis Extends 4-Year Survival in 1L Advanced Biliary Tract Cancer
Durvalumab is an anti–PD-L1 monoclonal antibody added to gemcitabine/cisplatin (GemCis) in the global, double-blind Phase 3 TOPAZ-1 first-line aBTC trial (NCT03875235). In this 4-year post hoc update (data cutoff…
NCT03875235 - Trial result
Liver and bile duct cancer
KRAS-mutant biliary tract cancer predicts shorter PFS on durvalumab + Gem/Cis
Gemcitabine/cisplatin plus durvalumab (GCD; PD-L1 blockade) was evaluated retrospectively in advanced biliary tract cancer patients treated front line at MSK with pretreatment tumor sequencing (n=236; 56%…
NCT01775072 - Trial result
Liver and bile duct cancer
Pemigatinib (FGFR1–3 inhibitor) improves PFS and ORR vs Gem/Cis in 1L FGFR2-rearranged mCCA (FIGHT-302)
Pemigatinib is an oral selective FGFR1–3 tyrosine kinase inhibitor evaluated as first-line therapy in the randomized global Phase 3 FIGHT-302 trial (NCT03656536) in previously untreated unresectable/metastatic…
NCT03656536 - Trial result
Liver and bile duct cancer
GemCis + Lenvatinib + Adebrelimab (VEGFR/FGFR/PD-L1) Hits 46% ORR in iCCA
Adebrelimab is a PD-L1 antibody and lenvatinib is an oral VEGFR/FGFR/RET/KIT multi-kinase inhibitor added to gemcitabine/cisplatin in a prospective, multicenter, single-arm Phase 2 first-line trial for…
NCT06298968 - Trial result
Liver and bile duct cancer
Tremelimumab (CTLA-4) + durvalumab (PD-L1) ± lenvatinib (VEGFR TKI) with TACE improves PFS in embolization-eligible unresectable HCC (EMERALD-3)
Tremelimumab + durvalumab (STRIDE: single priming dose tremelimumab plus Q4W durvalumab) was combined with transarterial chemoembolization (TACE) with or without lenvatinib (VEGFR/FGFR-targeting multikinase…
NCT05301842 - New trial
Liver and bile duct cancer
Phase 3 D07001 oral gemcitabine (deoxycytidine antimetabolite) + capecitabine in advanced BTC
In this Phase 3, randomized, double-blind, placebo-controlled, multicenter study (Inno-GO-07), InnoPharmax is testing whether adding D07001-softgel capsules—an oral gemcitabine formulation (a deoxycytidine analog…
NCT06622057 Registrational - Trial result Spotlight
Liver and bile duct cancer
Nivolumab+Ipilimumab (PD-1+CTLA-4) Sustains OS Benefit in 1L Unresectable HCC; Deep Responses Track With Long Survival
Nivolumab (PD-1 inhibitor) plus ipilimumab (CTLA-4 inhibitor) was tested vs lenvatinib/sorafenib (TKI SOC options) in the Phase 3 CheckMate-9DW first-line unresectable HCC trial (NCT04039607; n=668), with nivolumab…
NCT04039607 - Trial result
Liver and bile duct cancer
Early sofosbuvir-based DAAs + atezolizumab/bevacizumab boosts circulating T-cells but yields 0% ORR in HCV-HCC
In the open-label, single-arm Phase IV NCT05717400 trial, patients with HCV-associated advanced HCC received first-line atezolizumab (PD-L1) plus bevacizumab (VEGF) alongside early direct-acting antivirals…
NCT05717400 - Trial result
Liver and bile duct cancer
Tegavivint (TBL1→nuclear β-catenin degradation) shows 22% ORR in Wnt-mutant 2L/3L aHCC
Tegavivint is a first-in-class IV small molecule that binds TBL1 to disrupt the TBL1/β-catenin complex, driving selective degradation of nuclear β-catenin (downstream Wnt/β-catenin inhibition). In this multicenter…
NCT05797805 - Trial result
Liver and bile duct cancer
Rilvegostomig (PD-1×TIGIT bispecific) + gem/cis posts 16.8-mo OS in 1L advanced BTC
Rilvegostomig (R) is a monovalent, Fc-reduced PD-1×TIGIT bispecific antibody designed to synchronously block PD-1 and TIGIT on immune effector cells; it was combined with gemcitabine/cisplatin in the global Phase 2…
NCT05775159 - Trial result
Liver and bile duct cancer
TheraSphere (Y-90 glass microspheres) SIRT delivers 21.8-mo real-world OS in HCC, with a clear ≥400Gy dose–survival signal
Yttrium-90 (Y-90) glass microsphere selective internal radiation therapy (SIRT; TheraSphere™) is a catheter-delivered liver-directed radiotherapy that treats HCC by delivering high beta radiation doses to tumor while…
- Trial result Spotlight
Liver and bile duct cancer
Muzastotug (ADG126) masked anti-CTLA-4 + atezolizumab/bevacizumab lifts ORR to 50% in 1L uHCC (tiny n)
Muzastotug (ADG126) is a protease-activated, Treg-depleting anti-CTLA-4 IgG1 designed for tumor-local activation (reported ~10× higher ADCC than ipilimumab) and was added to atezolizumab (PD-L1) + bevacizumab (VEGF)…
NCT04524871 - Trial result
Liver and bile duct cancer
Perioperative nivolumab ± relatlimab (PD-1/LAG-3) is surgery-safe and drives ~20%–27% major path responses in high-risk resectable HCC
Nivolumab is an anti–PD-1 monoclonal antibody, and relatlimab is an anti–LAG-3 monoclonal antibody (dual checkpoint blockade); both were tested as perioperative immunotherapy in an open-label, randomized,…
NCT04658147 - New trial
Liver and bile duct cancer
Phase 2 Yttrium-90 TARE beta-radiation embolization versus SBRT photon radiation for HCC
Henry Ford Health System is running REVERT, a single-site, prospective, randomized, open-label Phase 2 trial comparing two definitive local radiation strategies for hepatocellular carcinoma (HCC): transarterial…
NCT07530172 Exploratory - New trial
Liver and bile duct cancer
Phase 1 TheraBionic P1 device: Electromagnetic modulation therapy for advanced HCC
This trial assesses the safety and impact on overall survival of the investigational TheraBionic P1 device, which delivers self-administered amplitude-modulated electromagnetic fields, compared to a secondary…
NCT07118202 Exploratory - New trial
Liver and bile duct cancer
Phase 2 trial of TheraSphere Yttrium-90 microspheres for liver internal radiation therapy
This prospective, single-arm, open-label Phase 2 trial at the University of California, San Francisco evaluates trans-arterial radiation segmentectomy for patients with unresectable hepatocellular carcinoma (BCLC…
NCT07110233 Exploratory - New trial
Liver and bile duct cancer
Phase I trial of CA-4948 IRAK4/FLT3 inhibitor combined with chemoimmunotherapy in advanced biliary cancer
This trial evaluates CA-4948, an IRAK4/FLT3 inhibitor, with gemcitabine (ribonucleotide reductase inhibitor), cisplatin (DNA synthesis inhibitor), and durvalumab (PD-L1 antibody) on a 21-day cycle in treatment-naïve…
NCT07107750 Exploratory - New trial
Liver and bile duct cancer
Phase 1b study: Ipilimumab (CTLA-4 mAb) and Nivolumab (PD-1 mAb) with SBRT for HCC
This pilot trial, sponsored by University of Hawaii, evaluates response-adapted SBRT and subsequent surgery following preoperative ipilimumab and nivolumab in patients with borderline resectable hepatocellular…
NCT07075120 Exploratory - New trial
Liver and bile duct cancer
Phase Ib/II Zanzalintinib Trial: cMet/VEGFR Inhibitor for Advanced Hepatocellular Carcinoma
This Phase Ib/II trial led by Northwestern University assesses zanzalintinib, a small molecule inhibitor of cMet and VEGFR, for safety, dose-finding, and preliminary effectiveness in patients with advanced…
NCT07042919 Exploratory - New trial
Liver and bile duct cancer
Phase 1 Feasibility Trial: Atezolizumab PD-L1 mAb & Bevacizumab VEGF mAb with Y90 Radioembolization
This single-institution, single-arm feasibility trial evaluates the combination of systemic atezolizumab (a PD-L1 targeting monoclonal antibody) and bevacizumab (a VEGF targeting monoclonal antibody) with…
NCT07059494 Exploratory - New trial
Liver and bile duct cancer
Phase 1 trial: Tremelimumab, CTLA-4 directed mAb combined with radiotherapy for HCC
This Phase 1 study tests a preoperative protocol combining three fractions of focused radiotherapy with one dose of Tremelimumab followed by Durvalumab every four weeks, in patients with resectable or advanced…
NCT06994299 Exploratory - New trial
Liver and bile duct cancer
Phase I/II trial of Pemigatinib FGFR1-3 inhibitor in advanced cholangiocarcinoma
This study, sponsored by M.D. Anderson Cancer Center, evaluates pemigatinib combined with atezolizumab and bevacizumab in patients with unresectable, advanced cholangiocarcinoma harboring FGFR2 fusion. The trial…
NCT06439485 Exploratory - New trial
Liver and bile duct cancer
Phase I/II Trial: Sapanisertib (mTORC1/2 inhibitor) and cabozantinib in β-catenin–mutated metastatic liver cancer
This trial compares sapanisertib plus cabozantinib versus cabozantinib monotherapy, evaluating safety, dosing, and efficacy in metastatic hepatocellular carcinoma patients (including a β-catenin-mutated subgroup) to…
NCT06811116
Looking for trials that fit a specific diagnosis? Read our guide on how to find a clinical trial, or subscribe to New in Oncology to get each issue by email.